We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Hybrigenics Participates in the MASTERSWITCH European Project

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Hybrigenics Participates in the MASTERSWITCH European Project"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced that it has signed a substantial contract as part of a large-scale European Union research project called MASTERSWITCH.

Hybrigenics will deploy its protein interaction expertise in the field of chronic inflammatory diseases. The company will develop a high throughput assay and screen its diverse 100,000 compound library and its collection of about 2,000 natural substances. The aim is to identify small-molecule inhibitors of a therapeutically relevant protein interaction.

A hit-to-lead optimization program will then be conducted in close collaboration with Dr. Frederique Ponchel (Leeds Institute of Molecular Medicine, UK) and Prof. Richard Aspinall (Translational Medicine, Cranfield University, UK).

Hybrigenics will receive more than EUR 400,000 over the first two years of the five year-long consortium agreement. "This EU contract is the recognition at international level of the excellence of Hybrigenics' expertise in this area of protein interaction assay development and screening," said Remi Delansorne, CEO at Hybrigenics.